Keywords: fda, issues, non-approvable, letters, indevus, valstar, pharmacyclics
FDA issues "non-approvable" letters for Indevus' Valstar and Pharmacyclics
Article | 07 January 2008
The US Food and Drug Administration issued a "non-approvable" letter for Pharmacyclics' Xcytrin (motexafin gadolinium) for non-small cell lung cancer ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
